Morphotek and Targeted Alpha Therapy Group to collaborate in ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Morphotek Inc., a subsidiary of Eisai Inc., entered into an agreement with the Targeted Alpha Therapy Group at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an alpha therapy vector being studied for radioimmunotherapy in ovarian cancer.

Farletuzumab is an investigational humanized monoclonal antibody that binds to folate receptor alpha, a protein which is highly expressed in ovarian carcinoma but largely absent from normal tissue.

In radioimmunotherapy, mAbs are attached to radioisotopes that may potentially deliver highly cytotoxic radiation in a targeted and more direct way to relevant cancer cells. The use of alpha emitters, in contrast to beta emitters, may potentially allow for the killing of only targeted cells binding with the vector due to the short alpha particle track. This collaboration will initially investigate the use of farletuzumab as an alpha therapy vector in preclinical laboratory studies, followed by the overall objective, which is to investigate in clinical trials the safety and efficacy of alpha-radiolabeled farletuzumab in women who enter remission upon completion of first-line treatment.

Farletuzumab is currently being tested in a clinical study in first-relapsed, platinum-sensitive ovarian cancer patients with low CA125 levels. The double-blind, randomized-controlled study is designed to prospectively evaluate the clinical effects observed in the previously conducted phase III trial in the pre-specified subset of patients treated with farletuzumab exhibiting low CA125 levels.

The TAT Group’s research activities will be coordinated by various departments at the Sahlgrenska Academy, University of Gothenburg, under the direction of Associate Professor Per Albertsson, an oncologist at Sahlgrenska University Hospital.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login